Propylene glycol diacetate (PGDA) is a colorless low-viscosity solvent with a slight ether-like odor. The Dow Chemical Company (Dow) manufactures and sells PGDA and other propylene oxide-based glycol ethers under the trade name DOWANOL Glycol Ethers. Propylene glycol diacetate may be used as an emulsifier, solubilizer or solvent in pharmaceuticals.

Estriol acetate benzoate is a semisynthetic, steroidal estrogen. Estriol benzoate diacetate is reported as an ingredient of Holin in Japan. It is an estrogen receptor agonist.

Hexestrol diacetate (brand name Retalon-Lingual among others) is an ester of hexestrol. It is a synthetic estrogen that was used for the treatment of menstruation disorder. It is an estrogen receptor agonist. A single therapeutic dose of hexestrol diacetate administered in impuber sheep has been shown to induce massive follicular atresia. So the incorrect utilisation of some hormonal formulations and the consumption of forages that contain estrogen like compounds, can represent major causes of infertility in sheep.

Acetomenaphthane, A vitamin K analogue used to treat and prevent hypoprothrombinemia caused by vitamin K deficiency. Also called menadiol diacetate. Hypoprothrombinemia is a blood disorder in which a deficiency of prothrombin results in impaired blood clotting, leading to an increased physiological risk for bleeding, especially in the gastrointestinal system, cranial vault, and superficial integumentary system.

Terlipressin (Glypressin) is indicated for the treatment of bleeding oesophageal varices and in some countries for the treatment of hepatorenal syndrome type 1. It is a prodrug and is converted to the lysine vasopressin in the circulation after the N-triglycyl residue is cleaved by endothelial peptidases. This results in a ‘slow release’ of the vasoactive lysine vasopressin. Terlipressin exerts its action by activating V1a, V1b and V2 vasopressin receptors. On September 14, 2022, the FDA granted approval to terlipressin (Terlivaz) for the treatment of adults hospitalized with hepatorenal syndrome with rapid reduction in kidney function (HRS-1). Prior to the approval, no approved treatment for this condition existed in the United States.